Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Relapsed or Refractory Mantle Cell Lymphoma
2023-509352-34-00Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib in mantle cell lymphoma (MCL), sponsored by Acerta Pharma. Primary endpoint: Overall response rate (ORR). Started Jun 2024; status: completed.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2023-509352-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509352-34-00.